This year 2010, trauma-related conditions accounted for $82.3 billion in healthcare expenditures, making that band of conditions the second costliest of all health conditions – surpassed only by heart conditions. Section 3505 of the Affordable Care Act authorizes $100 million in annual grants to help defray considerable uncompensated care costs, further the core mission of trauma centers, and offer emergency relief to ensure the continued option of trauma providers. According the study authors, the money have yet to be appropriated by Congress. They argue that complete funding of these provisions is needed to stabilize statewide trauma systems that are struggling to survive, including the ones that provide regionalized look after other time-sensitive emergency conditions, such as heart and stroke conditions.Through annual Discussion Meetings on specific topics, ECNP aims to facilitate the dialogue and exchange of suggestions between the participating parties, i.e. Scientists, regulatory authorities and the pharmaceutical industry. Invitation: meet up with the scientists! Specialists will be accessible for questions by journalists throughout press conferences at the 23rd ECNP Congress. The 23rd ECNP Congress will once present a high-calibre and balanced scientific programme again, in which the latest achievements and upcoming perspectives in neuropsychopharmacology and related disciplines of virtually all disorders of the brain are discussed, including the various aspects of pharmacotherapy in order to enhance the life of patients with psychiatric and neurological disorders.
AFFiRiS to commence Phase II trial of its Alzheimer’s vaccine candidate AFFiRiS AG will concentrate its Alzheimer’s vaccine system on one product candidate in an unexpectedly early stage of development: the vaccine candidate Advertisement02 is planned to enter into Phase II clinical trial early this year 2010.